Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | BBOX1 | O75936 | 7/20 | 0.39 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | CRAT | P43155 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycinebetaine SCHEMBL7739 | 0.77 | — | — | |
| Betaine SCHEMBL31467313 | 0.77 | — | — | |
| Glycinebetaine SCHEMBL8678519 | 0.77 | TSHR (0.53) | CA4TSHRALDH1A1LMNAAPEX1 | |
| Glycinebetaine SCHEMBL4900209 | 0.77 | — | — | |
| Glycinebetaine SCHEMBL2803780 | 0.77 | TSHR (0.53) | CA4TSHRALDH1A1LMNAAPEX1 | |
| SCHEMBL12557080 | 0.76 | TSHR (0.59) | TSHRALDH1A1LMNAAPEX1BBOX1 | |
| Glycinebetaine SCHEMBL156936 | 0.76 | TSHR (0.46) | CA4TSHRALDH1A1LMNAAPEX1 | |
| SCHEMBL234229 | 0.76 | TSHR (0.60) | TSHRALDH1A1LMNAAPEX1MEN1 | |
| Glycinebetaine SCHEMBL8725957 | 0.75 | — | — | |
| Glycinebetaine SCHEMBL20703289 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118178224-A | Anti-aging and antioxidant mask and preparation method thereof | 南通大学 | 2024-06-14 | — | — | CN | disclosed |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2024-05-23 | — | — | US | disclosed |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION | 2024-05-02 | — | — | US | disclosed |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024010854-A1 | RAPID GENERATION OF BREATH-BASED HEALTH REPORTS AND SYSTEMS FOR USE IN THE SAME | DIAGNOSE EARLY, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-4299064-A2 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11835503-B2 | TMA-formation inhibitor treatment for elevated TMA-containing compound diseases | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3641748-B1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | CLEVELAND CLINIC FOUND (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| CN-115728256-A | Seminal plasma carnitine assay kit | 深圳市盛信康科技有限公司 | 2023-03-03 | — | — | CN | disclosed |
| US-20220065829-A1 | TRIMETHYLAMINE-CONTAINING COMPOUNDS FOR DIAGNOSIS AND PREDICTION OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| CN-107121540-B | Application of acylcarnitine spectrum or detection reagent thereof in prediction of onset risk of type 2 diabetes | 中国科学院上海营养与健康研究所 | 2020-06-12 | — | — | CN | disclosed |
| US-8168823-B2 | Process for the preparation of betaines | LONZA LTD (CH) | 2012-05-01 | — | — | US | disclosed |
| EP-2231587-B1 | PROCESS FOR THE PREPARATION OF BETAINES | LONZA AG (CH) | 2011-09-07 | — | — | EP | disclosed |
| US-20100267986-A1 | PROCESS FOR THE PREPARATION OF BETAINES | LONZA LTD (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | SLC5A2, SLC5A1, MAT1A | CA4 2509/4885TSHR 2759/4885ALDH1A1 1973/4885 |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | MAOB, DAO, ESD | CA4 1697/4885TSHR 3915/4885ALDH1A1 239/4885 |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | SLC5A2, SLC5A1, MAT1A | CA4 2509/4885TSHR 2759/4885ALDH1A1 1973/4885 |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | CA4 1697/4885TSHR 3915/4885ALDH1A1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.